{"name":"Fenix Innovation Group","slug":"fenix-innovation-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NTI164","genericName":"NTI164","slug":"nti164","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"NTI164","genericName":"NTI164","slug":"nti164","phase":"phase_3","mechanism":"NTI164 is a small molecule that acts as a selective inhibitor of the SGLT2 transporter.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPdVNldllTTmtncFdlVDZNV1JQWmRHQlFIZ2t4Tmh6RHo3YTJkYklDMTN4ZWVQOFBkaGZoVE9aTWZ5ODdwM1pnVnVyaTBBWUhLMC1vRVRLbE1FMUtHYXBDeWE3OEEydlBpa3E0aFg1ZUh5Q2R6Q1hpdmJvS2pkSnFsRUJtaF9waHMxdUlIMEw2UE0tRzhTdUw5angzVQ?oc=5","date":"2026-02-23","type":"pipeline","source":"Fierce Pharma","summary":"Obesity Power Rankings: Who will challenge Lilly and Novo? - Fierce Pharma","headline":"Obesity Power Rankings: Who will challenge Lilly and Novo?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOMWQzcmpYY3dpU3NBSDFONTNzaERKMzRNV1hCWll1aGdWcERHNDlRdm1iRGNRaFFiWlZEcHFZcG9WQk5zVlJqVmJ0Y1oxdkFZanlnSXd3U0hkSFFMMFlybERjZ3o1QTMtY2FnQS1kMUY1elQ3U1VTR2FHTjluWlR3M1ZOQnJudXVpVTlWRkRndjhiQzZFZThPUHhEUkwxRnFkQ3pQQmw1bGJXTXUxVW5aaXdWTkY1cFU?oc=5","date":"2024-04-10","type":"trial","source":"smallcaps.com.au","summary":"Neurotech International admits final patient for NTI164 Phase II/III trial to treat autism - smallcaps.com.au","headline":"Neurotech International admits final patient for NTI164 Phase II/III trial to treat autism","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}